01.08.18: Not intended for U.S. and UK Media

Bayer receives approval of new treatment regimen for Eylea® in the EUNew treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains / Data from ALTAIR study demonstrate sustainability of new approach in 57% of patients who extended their treatment interval to 12 weeks or moremehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news